Complete Decongestive Therapy in Breast Cancer-Related Lymphedema

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to investigate which number of lymphedema therapy treatments/week best reduces upper extremity swelling, increased arm function, and reduces the most lymphedema symptoms.

Clinical Trial Description

Complete Decongestive Therapy (CDT) is the "gold standard" in lymphedema care and has been found to be efficacious in numerous studies. These studies have varying treatment protocols of intensive phase I CDT with dosing ranging from 2x/wk for a mean of 7.5 wks to 6x/wk until a plateau in arm volumes were achieved. This variability in research does not lend itself to recommendations of evidence-based protocol use of CDT in an outpatient setting.

Although CDT is backed by efficacy studies, the daily dosing given to patients is based on anecdotal rather than evidence-based practice. Because the traditional protocol was developed from "longstanding experience," research is necessary to determine the best dosing of the intensive phase of CDT. The purpose of this study is to investigate what level of dosing in the intensive CDT phase promotes best volume reduction and increased upper extremity function in the breast cancer-related lymphedema patient population. This particular study will answer: What dosing produces best volumetric reduction and upper extremity function in the intensive phase of complete decongestive therapy for outpatients with breast cancer-related lymphedema 2x/wk for 4wks or 4x/wk for 4 wks? ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02458391
Study type	Interventional
Source	University of Indianapolis
Contact
Status	Withdrawn
Phase	N/A
Start date	July 2015
Completion date	July 2015

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04858230` - LymphoPilot Test for Limb Lymphedema	N/A
Completed	`NCT04575636` - MRL in the Upper Extremity	N/A
Completed	`NCT03252145` - Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device	N/A
Active, not recruiting	`NCT05441943` - Lymphaticovenous Anastomosis as Treatment for Lymphedema	N/A
Completed	`NCT05754346` - Does Inclusion of Diaphragmatic Breathing Exercises in Complete Decongestive Therapy Provide Further Benefits in Patients With Breast Cancer Related Lymphedema	N/A
Not yet recruiting	`NCT06264817` - Auto-Adjustable MOBIDERm Autofit Armsleeve in the Management of Upper Limb Lymphedema.	N/A
Completed	`NCT06399458` - The Relationship Between Primary Lymphedema and Joint Hypermobility
Recruiting	`NCT06302361` - Lymphovenous Anastomosis for Breast Cancer Lymphedema	N/A
Active, not recruiting	`NCT06278298` - Different Level of ECSWT in Post Mastectomy Lymphedema	N/A
Completed	`NCT05037708` - Effects of Physiotherapy in the Treatment of Lymphedema After Breast Cancer	N/A
Not yet recruiting	`NCT02453295` - Testing an Intervention to Foster Hope for Cancer Survivors With Lymphedema	N/A
Completed	`NCT05660590` - Effect of Different Bandage Interface Pressures on Breast Cancer Related Lymphedema	N/A
Completed	`NCT04766489` - Evaluation of the Treatment Response in Breast Cancer Related Lymphedema	N/A
Enrolling by invitation	`NCT04165512` - Effectiveness of Stellate Ganglion Block in Breast Cancer Related Lymphedema	N/A
Recruiting	`NCT05762224` - Comparative Effects of KT and PG on UE Lymphedema and Functional Disability After Mastectomy	N/A
Recruiting	`NCT06082349` - The N-LVA Study: RCT Comparing LVA vs. Sham Surgery in Cancer-related Lymphedema	N/A
Recruiting	`NCT05142800` - Screening For BCRL In Targeted Therapy For Breast Cancer
Recruiting	`NCT06012786` - Myofascial Pain Syndrome in Patients With Breast Cancer-related Lymphedema
Not yet recruiting	`NCT06113627` - Lymphatic Response to Resistance Exercise in Breast Cancer Survivors	N/A
Completed	`NCT06036173` - Body Awareness and Functionality in Lymphedema